[{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AST-008","moa":"TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AST-008","moa":"TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"ISA Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Human Papillomavirus Vaccine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ ISA Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ ISA Pharmaceuticals"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"CD28","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vyriad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Vyriad","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vyriad \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vyriad \/ Not Applicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BNT111","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ Regeneron","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Regeneron"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"MAIA Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","graph1":"Oncology","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ MAIA Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron Pharmaceuticals \/ MAIA Biotechnology"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Checkmate Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Cemiplimab","moa":"TLR9","graph1":"Oncology","graph2":"IND Enabling","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals"},{"orgOrder":0,"company":"Replimune","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"BNT111","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ISA Pharmaceuticals \/ Regeneron","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Regeneron"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"BNT111","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Not Applicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ BioNTech"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"KRAS","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Elicio Therapeutics \/ Regeneron","highestDevelopmentStatusID":"4","companyTruncated":"Elicio Therapeutics \/ Regeneron"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Cemiplimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.1000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Regeneron","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Regeneron"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ ThinkEquity"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ ThinkEquity"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PSMA\/CD28","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"CD163","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OncoResponse \/ Regeneron","highestDevelopmentStatusID":"4","companyTruncated":"OncoResponse \/ Regeneron"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"CD223","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Replimune \/ Hercules Capital","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Hercules Capital"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Roche Diagnostics GmbH \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Roche Diagnostics GmbH \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"LILRB","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Ad-RTS-hIL-12","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Alaunos Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Therapeutics \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Replimune","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"Replimune \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Replimune","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Replimune \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ J.P. Morgan"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Sensei Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron Pharmaceuticals \/ Sensei Biotherapeutics"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Series B Financing","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Grey Wolf Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Grey Wolf Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Grey Wolf Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Cemiplimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.1000000000000001,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Grey Wolf Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HotSpot Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ ThinkEquity"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ ThinkEquity"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OncoNano Medicine \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ankyra Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ankyra Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MAIA Biotechnology \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medison Pharma \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Medison Pharma \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"GENESIS Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GENESIS Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GENESIS Pharma \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"GENESIS Pharma \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SillaJen, Inc \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoResponse \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ISA Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"FibroGen \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"FibroGen \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"BNT111","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioNTech \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","graph1":null,"graph2":null,"graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":null,"companyTruncated":"MAIA Biotechnology \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Cemiplimab
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target